Cite
HARVARD Citation
Urba, W. et al. (2015). A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].